^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFRvIII inhibitor

    Related drugs:
    1m
    The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma. (PubMed, Clin Exp Med)
    Although phase I clinical studies with AMG 596 have shown acceptable safety profiles and early indications of efficacy, preclinical mice have demonstrated prolonged longevity...Promising developments include novel approaches such as multivalent targeting, DNA-encoded or cell-delivered TCEs, and combinations with immune checkpoint inhibitors (ICIs) or CAR-T cells. With an emphasis on its integration into multimodal treatment approaches, this review highlights the safety, effectiveness, and potential uses of TCEs immunotherapy for gliomas.
    Review • Journal
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    etevritamab (AMG 596)
    1m
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
    |
    WSD0922
    2ms
    A Phase I/II Study to Evaluate EGFR-TKIs in the Treatment of Subjects with Non-Small Cell Lung Cancer (ChiCTR2500108653)
    P1/2, N=78, Recruiting, Shanghai East Hospital; Hangzhou Weiruibao Biopharm Co., LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • WSD0922 • simmitinib (SYHA1817)
    3ms
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=55, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2030
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
    |
    WSD0922
    4ms
    WAYWIN103: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Wayshine Biopharm, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • WSD0922
    5ms
    A Phase I/II Study to Evaluate EGFR-TKIs in the Treatment of Subjects with Non-Small Cell Lung Cancer (ChiCTR2500108653)
    P1/2, N=78, Not yet recruiting, Shanghai East Hospital; Hangzhou Weiruibao Biopharm Co., LTD.
    New P1/2 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • WSD0922
    6ms
    WAYWIN103: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Wayshine Biopharm, Inc.
    New P1/2 trial
    |
    Tagrisso (osimertinib) • WSD0922
    6ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Active, not recruiting --> Recruiting | N=43 --> 60 | Trial completion date: Dec 2025 --> Dec 2026
    Enrollment open • Enrollment change • Trial completion date
    |
    GNC-039
    6ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=147 --> 43
    Enrollment closed • Enrollment change
    |
    GNC-039
    6ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=147, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    GNC-039
    7ms
    A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Wayshine Biopharm, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • WSD0922
    7ms
    A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Wayshine Biopharm, Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    WSD0922